Exploring the effects of Lisdexamfetamine (Venvanse) on students: Perspectives on Attention Deficit Hyperactivity Disorder (ADHD), Binge Eating Disorder (BED), and associated complications
DOI:
https://doi.org/10.33448/rsd-v14i10.49686Keywords:
ADHD, Lisdexamfetamine Dimesylate, Binge-Eating Disorder, Prescription Drug Misuse, Students.Abstract
Lisdexamfetamine dimesylate (LDX) is a prodrug widely used in the treatment of attention deficit hyperactivity disorder (ADHD) and binge eating disorder (BED). Despite its therapeutic efficacy, concerns regarding misuse, adverse effects, and interactions with other psychiatric conditions have been increasing, especially among students. To conduct a systematic review on the benefits, mechanisms of action, complications, and patterns of non-medical use of LDX, focusing on student populations, aiming to guide safer prescribing practices. Following PRISMA guidelines, databases such as PubMed, SciELO, and Medline were consulted using search strategies with Boolean operators and keywords related to LDX, ADHD, BED, and misuse. Clinical studies, systematic reviews, and case reports published between 2019 and 2024 were included, while theses and unpublished data were excluded. LDX demonstrated significant efficacy in reducing binge eating episodes (up to 64%) and ADHD symptoms (40% improvement in assessment scales). However, a high risk of non-medical use was identified among students (7.8% in North American universities), associated with cardiovascular complications, overdose, and dangerous interactions with antidepressants. Its mechanism of action involves dopaminergic and noradrenergic modulation, with a superior safety profile compared to traditional amphetamines, though still subject to adverse effects such as hypertension, tachycardia, and insomnia. Lisdexamfetamine is an effective therapeutic option for ADHD and BED; however, its use requires rigorous monitoring, patient education, and more effective regulation to mitigate risks of misuse and complications, especially in academic settings.
References
AbdelSalam, F. M. (2023). Blockchain Revolutionizing Healthcare Industry: A Systematic Review of Blockchain Technology Benefits and Threats. Perspect Health Inf Manag. 20(3):1b. https://pmc.ncbi.nlm.nih.gov/articles/PMC10701638/.
Anton, M. E., Altomare, A. L., Blais, A. R., Patten, J. C., Fjeld, K. J., Esteves, A. M. & Roginski, M. A. (2024). Reducing Deep Sedation and Benzodiazepine Use in Mechanically Ventilated Patients During Critical Care Transport: A Quality Improvement Initiative. Air medical journ.al 43(6), 512–7.
Arria, A. M. & Wish, E. D. (2006). Nonmedical use of prescription stimulants among students. The Pediatric clinics of North America. 53(1), 215–27.
Bendit, A. & Mariani, M. (2024). The Implementation of Universal Mental Health Screening in an Early College High School Program. Professional School Counseling. 28(1).
Barkla, X. M., Mcardle, P. A. & Newbury-Birch, D (2023). Are there any potentially dangerous pharmacological effects of combining ADHD medication with alcohol and drugs of abuse? A systematic review of the literature. BMC Psychiatry. 15, 270.
Chagas, R. F., Souza, J. V. L. de, Barbosa, J. M., Pegoraro , F. & Sousa, S. F. (2025). A prevalência do uso de lisdexanfetamina entre universitários do curso de medicina de uma Universidade no Sul do Tocantins. Observatório de la economía latinoamericana. 23(1), e8844.
Chen, L. Y. et al. (2019). Patterns of concurrent substance use among adolescent nonmedical ADHD stimulant users. Addictive Behaviors. 49, 1–6.
de Oliveira, M. C. T. & Guimarães Neto, A. C. (2024). Uso estendido de medicamentos psicoestimulantes em estudantes. Revista Brasileira de Revisão de Saúde. 7 (1), 1440–59.
da Silva Almeida, R., Lima Vieira, C., Ribeiro Pinto, C., Vicente Rodrigues, L. & Cardoso De Morais Oliveira., V. (2024). ID208 Eficácia e segurança do uso da lisdexanfetamina no tratamento do transtorno de déficit de atenção e hiperatividade em indivíduos entre 6 e 17 anos: uma revisão sistemática e meta-análise: eixo 1: sustentabilidade nos sistemas de saúde. Jornal de Assistência Farmacêutica e Farmacoeconomia, 9 (s.1).
Ermer, J. C., Dennis, K., Haffey, M. B. et al. (2011). Administração intranasal versus oral de dimesilato de lisdexanfetamina. Clin. Investigação de Drogas. 31, 357–70.
Faraone, S. V., Banaschewski, T., Coghill, D., Zheng, Y., Biederman, J., Bellgrove, M. A., Newcorn, J. H., Gignac, M., Al Saud, N. M., Manor, I., Rohde, L. A., Yang, L., Cortese, S., Almagor, D., Stein, M. A., Albatti, T. H., Aljoudi, H. F., Alqahtani, M. M. J., Asherson, P., Atwoli, L., …& Wang, Y. (2021). The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. Neuroscience and biobehavioral reviews. 128, 789–818.
Flamm, A. & Hieger, M. A. (2019). Lisdexamfetamine Overdose. American Journal of Therapeutics. 26(6), e770–e771.
FDA. (2025). Obesity and overweight: Developing drugs and biological products for weight reduction guidance for industry (Draft Guidance, Revision 2). U.S. Department of Health and Human Services. Food and Drug Administration (FDA) https://www.fda.gov/regulatory-information/search-fda-guidance-documents.
Giacobbe, P. et al (2018). Efficacy and tolerability of lisdexamfetamine as an antidepressant augmentation strategy: A meta-analysis of randomized controlled trials. Journal of Affective Disorders. 226, 294–300.
Gury, C. & Cousin, F. (1999). Pharmacocinétique des ISRS: notion de demi-vie d'élimination et implications cliniques [Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability]. L'Encephale. 25(5), 470–6.
Haddaway, N. R., Page, M. J., Pritchard, C. C. & McGuinness, L. A. (2022). PRISMA2020: Um pacote R e aplicativo Shiny para produzir diagramas de fluxo em conformidade com o PRISMA 2020, com interatividade para transparência digital otimizada e Open Synthesis. Campbell Systematic Reviews. 18, e1230.
Heal, D. J., Smith, S. L., Gosden, J. & Nutt, D. J. (2013). Amphetamine, past and present--a pharmacological and clinical perspective. Journal of psychopharmacology (Oxford, England). 27(6), 479–96.
Higgs, S. & Spetter, M. S. (2018). Cognitive Control of Eating: the Role of Memory in Appetite and Weight Loss. Current Obesity Reports. 7(1), 50–9.
Hudson, J. I. et al. (2017). Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 74(9), 903–10.
ISSUP. (2024). Taxonomy. Term. Substance Abuse and Mental Health Services Administration (SAMHSA). International Society of Substance Use Prevention and Treatment Professionals (ISSUP). https://www.issup.net/pt-br/taxonomy/term/1918.
Jasinski, D. & Krishnan, S. (2009). Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. Journal of Psychopharmacology. 23(4):419-27.
Lenartowicz, A., Mazaheri, A., Jensen, O. & Loo, S. K. (2018). Aberrant Modulation of Brain Oscillatory Activity and Attentional Impairment in Attention-Deficit/Hyperactivity Disorder. Biological psychiatry. Cognitive neuroscience and neuroimaging. 3(1), 19–29.
Maneeton, N. et al. (2015). Comparative efficacy, acceptability, and tolerability of lisdexamfetamine in child and adolescent ADHD: a meta-analysis of randomized, controlled trials. Drug Design, Development and Therapy, p. 1927.
Maciel, F. D. et al. (2023). Segurança e eficácia do dimesilato de lisdexanfetamina em transtorno de déficit de atenção e hiperatividade: uma revisão literária. Research, Society and Development. 12(2), e28412240259.
Malachias, M. V. B., Kaiser, S. E., Albuquerque, D. C., Brandão, A. A., Sposito, A. C., Moura, L. Z., Magalhães, L. B. N. C., Mota-Gomes, M. A., Clausell, N., Jardim, P. C. V., Nadruz, W., Barros, B. M., Luna, L. C. & Barroso, W. K. S. (2024). Risk of Adverse Health Outcomes in Patients with Poor Adherence to Cardiovascular Medication Treatment: A Systematic Review. Arq Bras Cardiol. 107(3 Suppl 3). doi: 10.5935/abc.20160140.
Mccabe, S. E. et al. (2004). Prevalence and correlates of illicit methylphenidate use among 8th, 10th, and 12th grade students in the United States, 2001. Journal of Adolescent Health. 35(6), 501–4.
Mcelroy, S. L. et al. (2015). Efficacy and Safety of Lisdexamfetamine for Treatment of Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 72(3), 235–46.
Mingzohn, E. K. & Klein-Schwartz, W. (2015). Comparison of lisdexamfetamine and dextroamphetamine exposures reported to U.S. poison centers. Clinical Toxicology. 53(5), 477–85.
Page, M. et al. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 372(71). https://doi.org/10.1136/bmj.n71.
Pereira, A. S. et al. (2018). Metodologia da pesquisa científica. [e-book]. Editora da UAB/NTE/UFSM.
Prakash, S. et al. (2021). Antiepileptic drugs and serotonin syndrome- A systematic review of case series and case reports, Seizure. 91, 117-31.
Rubia, K., Alegria, A. & Brinson, H. (2014). Imaging the ADHD brain: disorder-specificity, medication effects and clinical translation. Expert review of neurotherapeutics. 14(5), 519–38.
Schaeffer, T (2012). Abuse-Deterrent Formulations, an Evolving Technology Against the Abuse and Misuse of Opioid Analgesics. Journal of Medical Toxicology. 8(4), 400–7.
Schneider, E., Higgs, S. & Dourish, C. T. (2021). Lisdexamfetamine and binge-eating disorder: A systematic review and meta-analysis of the preclinical and clinical data with a focus on mechanism of drug action in treating the disorder. European Neuropsychopharmacology. 53, 49–78.
Scotton, W. J., Hill, L. J., Williams, A. C. & Barnes, N. M. (2019). Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions. International journal of tryptophan research: IJTR, 12, 1178646919873925.
Segal, D. S. & Kuczenski, R. (1997). An escalating dose "binge" model of amphetamine psychosis: behavioral and neurochemical characteristics. The Journal of neuroscience : the official journal of the Society for Neuroscience, 17(7), 2551–66.
Steffen, K. J. et al. (2021). Lisdexamfetamine Pharmacokinetic Comparison Between Patients Who Underwent Roux-en-Y Gastric Bypass and Nonsurgical Controls. Obesity Surgery. 31(10), 4289–94.
Siemińska, L., Buntner, B., Wodniecki, J. & Swietochowska, E. (1994). Zmiany stezenia noradrenaliny i adrenaliny we krwi po próbie wysiłkowej i stymulacyjnym teście wieńcowym u chorych z choroba niedokrwienna serca [Changes in levels of noradrenaline and adrenaline in blood after exercise testing and transesophageal atrial pacing in patients with ischemic heart disease]. Przeglad lekarski, 51(7), 296–299.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Lucas Almeida Eidt, Dirce Maria Ignácio dos Santos Gonzaga, Luan Souza do Nascimento, Wagner Rafael da Silva
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
